ASCO 2008

Report from ASCO 2008

34,000 people attended this year's ASCO Conference in Chicago, IL. Of those, 26,600 were professionals, i.e. oncologists, oncology nurses, pharmacologists, and other health care professionals. Most of the others were exhibitors. International attendees, representing 117 countries, outnumbered domestic ones by 53% to 47%.

With respect to kidney cancer, three were neither surprises nor exceptional revelations in the more than 100 abstract presented in kidney cancer. There is a steady progression of work being done in targeted therapies, which is understandable given the early successes of sunitinib (Sutent) and sorafenib (Nexavar). We are reporting on updates to drug trials that have been ongoing for the last few years, including the first overall survival data coming out of a sunitinib trial, as well as some new treatments including immunotherapies.

Following are summary reports of selected oral and poster sessions.

ASCO 2008 Contents: